SAN FRANCISCO and SUZHOU, China, May 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other...
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025 )
Also on site :
- Emmy Predictions: Talk/Scripted Variety Series — The Variety Categories Are Still a Mess; Netflix, Dropout, and ‘Hot Ones’ Stir Up Buzz
- Ex-Bellingcat child porn researcher commits suicide after conviction for abusing own child – media
- Khloe Kardashian and Podcaster Totally Gush Over Each Other and Fans Are Swooning